Efficacy and safety of lansoprazole 30 mg versus omeprazole for 21 days treatment of acute esophagitis

Rampal, Patrick; Courrier, A.; Lemerez, M

doi:10.1016/0016-5085(95)23462-4

Cited by 5 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We initially identified nine randomized controlled trials 8 –16 . We excluded one because it had not been conducted according to a double‐blind design 14 .…”

Section: Resultsmentioning

confidence: 99%

“…We excluded one because it had not been conducted according to a double‐blind design 14 . Another was excluded because it reported healing rates after 3 weeks rather than 4 or 8 weeks 15 . We excluded a third because it compared lansoprazole 30 mg with omeprazole 40 mg 16 .…”

Section: Resultsmentioning

confidence: 99%

“…14 Another was excluded because it reported healing rates after 3 weeks rather than 4 or 8 weeks. 15 We excluded a third because it compared lansoprazole 30 mg with omeprazole 40 mg. 16 Of the six trials remaining, there was complete agreement among the authors regarding their suitability for inclusion. 8±13 All were published in the English language except for one, which was published in French.…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Meta‐analysis of randomized controlled trials comparing standard clinical doses of omeprazole and lansoprazole in erosive oesophagitis

Sharma

Leontiadis

Howden

2001

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Proton pump inhibitors are the drugs of choice for the treatment of erosive oesophagitis. In comparative clinical trials and in meta-analyses, they have been shown to be superior to H 2 -receptor antagonists in healing oesophageal erosions and in relieving associated symptoms. 1 For the different classes of antisecretory drugs, there is a statistically signi®cant linear relationship between suppression of 24-h intragastric acidity and oesophagitis healing rates. 2 In one comparative pharmacodynamic study, lansoprazole 30 mg o.d. produced a quantitatively greater degree of suppression of intragastric acidity than omeprazole 20 mg. 3 These doses of the two drugs are typically used in the treatment of erosive oesophagitis. Through the metaanalysis of randomized controlled trials, we wanted to determine whether the putative superior antisecretory effect of lansoprazole had been translated into a demonstrable advantage in healing rates. MATERIALS AND METHODSUsing the MEDLINE and EMBASE databases, two of the authors independently performed fully recursive literature searches for randomized controlled trials comparing omeprazole and lansoprazole in erosive oesophagitis. We used`omeprazole',`lansoprazole', and`oesophagitis' as text words and key words in the SUMMARY Background: Omeprazole and lansoprazole are used to treat erosive oesophagitis in the respective daily doses of 20 and 30 mg. Aim: To investigate, by meta-analysis, whether treatment with lansoprazole 30 mg increases erosive oesophagitis healing rates over omeprazole 20 mg. Methods: We searched for randomized, double-blind trials comparing omeprazole 20 mg and lansoprazole 30 mg in endoscopically diagnosed erosive oesophagitis. After assessing for homogeneity, non-heterogeneous trials were combined and pooled healing rates derived. We calculated the relative bene®t increase, absolute bene®t increase and number needed to treat.

show abstract

“…We initially identified nine randomized controlled trials 8 –16 . We excluded one because it had not been conducted according to a double‐blind design 14 .…”

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Meta‐analysis of randomized controlled trials comparing standard clinical doses of omeprazole and lansoprazole in erosive oesophagitis

Sharma

Leontiadis

Howden

2001

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…Both lansoprazole and omeprazole are known to be effective as short‐term treatment for acute oesophagitis. In a double‐blind study, 97 patients with peptic oesophagitis of grade IB, II, III or IV (Savary Miller) received treatment with lansoprazole 30 mg daily or omeprazole 20 mg daily for 21 days 60 . Endoscopy was performed at the start of the study and again after 21 days, and the results assessed first by the endoscopist and then by an independent group of experts who were blinded to the treatment regimen given.…”

Section: Clinical Efficacymentioning

confidence: 99%

An Overview of the Pharmacology, Efficacy, Safety and Cost‐effectiveness of Lansoprazole

2002

Int J Clinical Practice

View full text Add to dashboard Cite

SUMMARYLansoprazole is a proton pump inhibitor that reduces gastric acid secretion in a dose‐dependent manner via inhibition of H+/K+‐adenosine triphosphatase in gastric parietal cells. It also exhibits antibacterial activity against Helicobacter pylori in vitro. During almost 10 years of clinical use, lansoprazole has proved effective and well tolerated in a wide range of acid‐related disorders, including gastro‐oesophageal reflux disease (GORD), duodenal ulcers, gastric ulcers, non‐steroidal anti‐inflammatory drug‐related ulcers, as well as non‐ulcer dyspepsia and acid hypersecretion. It is also used, in combination with antibiotics, for H. pylori eradication. In the above indications, lansoprazole has generally proved to be superior to the histamine H2‐receptor antagonists, and is at least as effective as the other currently available proton pump inhibitors. This review aims to evaluate the pharmacology, efficacy, safety and cost‐effectiveness of lansoprazole in acid‐related disorders, with particular emphasis on its use in GORD and H. pylori eradication regimens.

show abstract

Lansoprazole: A Comprehensive Review

Zimmermann,

Katona

1997

Pharmacotherapy

View full text Add to dashboard Cite

Lansoprazole is the second member of the substituted benzimidazole class of antisecretory agents approved for use in the United States. These drugs decrease parietal cell acid secretion by inhibiting H+,K+‐adenosine triphosphatase, the final step in the secretion of acid. Lansoprazole has been studied extensively for the short‐term treatment of duodenal and gastric ulcers, reflux esophagitis, and Helicobacter pylori‐positive peptic ulcer disease; long‐term treatment of Zollinger‐Ellison syndrome; and maintenance treatment of erosive esophagitis. A dosage of 30 mg/day produced higher healing rates and equivalent or faster relief of ulcer symptoms than ranitidine or famotidine in patients with duodenal or gastric ulcers and reflux esophagitis. Compared with omeprazole 20 mg/day, that dosage provided faster epigastric pain relief in these patients after 1 week, although healing rates for the two agents were equivalent at 4 and 8 weeks. In patients with peptic ulcer refractory to 8‐week therapy with histamine2‐receptor antagonists, healing rates were not significantly different between lansoprazole and omeprazole. In patients with Zollinger‐Ellison syndrome, lansoprazole was superior to histamine2‐receptor antagonists and was similar in efficacy, safety, and duration of action to omeprazole. Combinations of lansoprazole or omeprazole with one or two antibiotics produced equivalent eradication of H. pylori. In clinical trials, lansoprazole was well tolerated, with frequency of adverse effects similar to that reported with ranitidine, famotidine, and omeprazole.

show abstract

Efficacy and safety of lansoprazole 30 mg versus omeprazole for 21 days treatment of acute esophagitis

Cited by 5 publications

References 0 publications

Meta‐analysis of randomized controlled trials comparing standard clinical doses of omeprazole and lansoprazole in erosive oesophagitis

Meta‐analysis of randomized controlled trials comparing standard clinical doses of omeprazole and lansoprazole in erosive oesophagitis

An Overview of the Pharmacology, Efficacy, Safety and Cost‐effectiveness of Lansoprazole

Lansoprazole: A Comprehensive Review

Contact Info

Product

Resources

About